Syngene International Limited
Syngene International Limited operates in Healthcare Research, Analytics & Technology, part of the Healthcare sector. It booked ₹833 cr of revenue in its latest quarter (Q2 FY27) and kept 3.9% of sales as profit. It is the largest of 5 Healthcare Research, Analytics & Technology companies we track, by market value.
“An Integrated Platform for Innovation Bayview biologics manufacturing facility, Maryland, USA Syngene is one of the largest integrated CRDMO players in India, operating at global scale with a one-stop platform for drug discovery, development and manufacturing.”
Healthier than 49% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 80–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 59
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in SYNGENE?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹833 cr |
| Other Income | ₹28 cr |
| Total Income | ₹861 cr |
| Cost of Materials | ₹203 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Inventory Change (±) | ₹-4 cr |
| Employee Benefit Expense | ₹273 cr |
| Finance Costs | ₹10 cr |
| Depreciation & Amortisation | ₹112 cr |
| Other Expenses | ₹214 cr |
| Total Expenses | ₹807 cr |
| Exceptional Items | ₹-7 cr |
| Profit before Tax | ₹47 cr |
| Tax Expense | ₹15 cr |
| Net Profit | ₹32 cr |
| Net margin on total income | 3.7% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 1,037 cr | 736 cr | 833 cr |
| Total income | 1,059 cr | 761 cr | 861 cr |
| Expenses | 857 cr | 767 cr | 807 cr |
| Profit before tax | 196 cr | -19 cr | 47 cr |
| Tax | 48 cr | -10 cr | 15 cr |
| Net profit (owners' share) | 148 cr | -9 cr | 32 cr |
| Net margin (owners' share, on revenue) | 14.3% | -1.2% | 3.9% |
| EPS (₹) | 3.68 | -0.22 | 0.80 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Syngene International Limitedthis company | ₹407 | ₹16,414 cr | 127.1 | 2.7% | 3.9% | — |
| Indegene Limited | ₹613 | ₹14,738 cr | 32.8 | 13.4% | 10.0% | — |
| Suven Life Sciences Limited | ₹261 | ₹6,895 cr | — | -86.3% | — | — |
| Vimta Labs Limited | ₹486 | ₹1,079 cr | 15.4 | 25.1% | 23.9% | — |
| TAKE Limited | ₹11 | ₹161 cr | 38.9 | 13.7% | 3.5% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1.25 / share | 25 Jun 2026 |
| Dividend | ₹1.25 / share | 27 Jun 2025 |
| Dividend | ₹1.25 / share | 28 Jun 2024 |
| Dividend | ₹0.5 / share | 30 Jun 2023 |
| Dividend | ₹0.75 / share | 30 Jun 2023 |
| Dividend | ₹0.5 / share | 30 Jun 2022 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 29 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.